key: cord-0428108-fvlifwdz
authors: Hume, Adam J; Heiden, Baylee; Olejnik, Judith; Suder, Ellen L; Ross, Stephen; Scoon, Whitney A; Bullitt, Esther; Ericsson, Maria; White, Mitchell R; Turcinovic, Jacquelyn; Thao, Tran TN; Hekman, Ryan M; Kaserman, Joseph E; Huang, Jessie; Alysandratos, Konstantinos-Dionysios; Toth, Gabor E; Jakab, Ferenc; Kotton, Darrell N; Wilson, Andrew A; Emili, Andrew; Thiel, Volker; Connor, John H; Kemenesi, Gabor; Cifuentes, Daniel; Mühlberger, Elke
title: Recombinant Lloviu virus as a model to study inaccessible zoonotic viruses
date: 2021-08-02
journal: bioRxiv
DOI: 10.1101/2021.08.02.454777
sha: d14bda78785bd3e3643d68d01864bada887df8de
doc_id: 428108
cord_uid: fvlifwdz

Next generation sequencing has revealed the presence of many RNA viruses in animal reservoir hosts, including many closely related to known human pathogens. Despite their zoonotic potential, many of these viruses remain understudied due to not yet being cultured. While reverse genetic systems can facilitate virus rescue, this is often hindered by missing viral genome ends. A prime example is Lloviu virus (LLOV), an uncultured filovirus that is closely related to the highly pathogenic Ebola virus. Using minigenome systems, we complemented the missing LLOV genomic ends and identified cis-acting elements required for LLOV replication that were lacking in the published sequence. We leveraged these data to generate recombinant full-length LLOV clones and rescue infectious virus. Recombinant LLOV (rLLOV) displays typical filovirus features, as shown by electron microscopy. Known target cells of Ebola virus, including macrophages and hepatocytes, are permissive to rLLOV infection, suggesting that humans could be potential hosts. However, inflammatory responses in human macrophages, a hallmark of Ebola virus disease, are not induced by rLLOV. We also used rLLOV to test antivirals targeting multiple facets of the replication cycle. Rescue of uncultured viruses of pathogenic concern represents a valuable tool in our arsenal against pandemic preparedness.

Zoonotic viruses are a major public health threat. A single spillover event from an animal host into the human population can initiate deadly epidemics or even pandemics. Bats play an important role as natural reservoirs of RNA viruses with the potential to cause significant harm to humans. CoV-2, and Ebola virus (EBOV), there is strong evidence that bats might be the natural reservoir, although these viruses have not yet been isolated from bats 1 . While some of these represent reemerging viruses that were already known to cause severe disease in humans, this list also includes a number of bat-borne viruses that were either unknown or understudied prior to spillover into the human population.

To better prepare for potential future zoonotic epidemics and pandemics, it is necessary to study newly discovered viruses that are closely related to highly pathogenic viruses to both determine their pathogenic potential and to develop and assess potential antiviral therapies. Since 2000, multiple new filoviruses have been discovered via next generation sequencing of samples from wild bats across the globe, including Lloviu virus (LLOV), Bombali virus, and Mengla virus [2] [3] [4] , but the ability to study these viruses has been limited because none of these new viruses have been cultured to date.

One particular virus of concern is LLOV, a filovirus whose viral RNA was initially isolated from carcasses of Schreiber's bats (Miniopterus schreibersii) in Spain and France using deep sequencing and PCR techniques and later found in the same species of bats in Hungary, although no infectious virus has been cultured to date 2, 5, 6 . Recently, LLOV re-emerged in bat populations in Northeast Hungary, and again its emergence correlated with unexplained increased mortality among Schreiber's bats 5 . Interestingly, many of the bats in which LLOV RNA was found showed symptoms of respiratory infection, but it remains to be determined if LLOV is the causative agent of the disease 2,5 . One worrying factor regarding the spillover potential for LLOV is the geographic range of the host species, Miniopterus schreibersii, which can be found across most of southern Europe, parts of northern Africa, and much of the Middle East, in which over 100 million people live. At the sequence level, LLOV is distinct enough from the ebola-and marburgviruses to be classified within its own genus Cuevavirus 7 . Although the pathogenic potential of LLOV remains unknown, similarities to EBOV and MARV raise concerns that it could be pathogenic for humans.

However, the pathogenicity of filoviruses varies considerably, highlighting the need to study LLOV in more detail.

Like many of the genomic sequences of these other uncultured RNA viruses, the LLOV genome is incomplete 2 . The lack of the terminal genomic sequences that orchestrate viral transcription and replication makes development of a fully wild-type reverse genetic system to rescue the virus impossible. Here we describe the complementation of the LLOV sequence with terminal genomic sequences from other filoviruses in mono-and bicistronic minigenome systems to determine the ability of these sequences to facilitate different aspects of the LLOV replication cycle. Leveraging the data from these complementation assays, we were able to develop a reverse genetic system that facilitated the rescue of infectious recombinant Lloviu virus complemented with sequences from EBOV or MARV (rLLOVcomp). We analyzed rLLOVcomp in various assays, ranging from ultrastructural analysis of infected cells to infection studies with primary human cells, antiviral testing, and host response analysis. Our data suggest that LLOV has the potential to infect humans but does not induce an inflammatory response in human macrophages, a hallmark of severe Ebola virus disease 8 . The success of this approach provides a roadmap for the rescue and characterization of other uncultured RNA viruses of pathogenic concern for which we currently only have incomplete genomic sequences.

As a member of the filovirus family, LLOV has a nonsegmented negative sense RNA genome.

The published LLOV genome sequence lacks four 3′ terminal nucleotides and almost the entire trailer region. Since the replication and transcription promoter regions of negative sense RNA viruses are contained within the genome ends, called the leader and trailer regions, the lack of the terminal sequences has hampered the generation of recombinant LLOV clones and viral rescue.

We previously showed that chimeric LLOV minigenomes that utilize the LLOV leader complemented with four 3ʹ terminal EBOV nucleotides in combination with the polymerase (L) gene 5ʹ noncoding region (encoding the 3ʹ UTR of the L mRNA) and trailer regions (UTR+tr) of EBOV, RESTV, and MARV are each replication and transcription competent 9 . To identify the most potent chimeric trailer region for use in full-length rLLOVcomp clones, we generated LLOV minigenomes containing the complete LLOV 5ʹ noncoding region including the sequence encoding the L 3ʹ UTR and the 8 known nucleotides of the LLOV trailer complemented with varying lengths of 5ʹ terminal sequences of the EBOV Mayinga genome (Fig. 1a) . Minigenomes with these chimeric LLOV-EBOV 5ʹ ends were functional, with a general trend of the shorter hybrid trailers being less active (Fig. 1b) . Of note, some of these LLOV minigenomes with chimeric trailers were more active than the LLOV minigenome utilizing the full 5ʹ end of EBOV (EBOVUTR+tr, Fig. 1b) . (a) Schematic of LLOV minigenomes with EBOV noncoding region (negative sense L gene 3ˈ UTR) and trailer (top) or hybrid 5ˈ ends consisting of the LLOV L gene 3ˈ UTR and trailer complemented with short terminal sequences from the EBOV trailer, designated LEX where X represents the number of added terminal nucleotides from EBOV. Le, leader; NP, nucleoprotein; L, polymerase; Tr, trailer. (b) Luciferase-based minigenome assays comparing the 3L5E 9 and chimeric 3L5LEX minigenomes. (c) Schematic of bicistronic 3L5LE72 minigenomes containing firefly and renilla luciferase reporters separated by either the wild-type LLOV VP24-L intergenic region (IRwt) or the same intergenic region with an inserted gene border (IRins) consisting of overlapping LLOV gene end (GE, red bar) and gene start (GS, green triangle) signals. (d) Luciferase-based minigenome assays comparing the bicistronic minigenomes. (e) Schematics of successfully rescued rLLOVcomp full-length clones. Noncoding regions are indicated in light gray, LLOV ORFs are in gray, a ZsGreen-P2A reporter (ZsG) is in light green, red bars and green triangles indicate the GE and Gs signals in the IRins insertion in the VP24-L intergenic region, green indicates EBOV sequences (EBOVUTR+tr), pink indicates short EBOV trailer sequences (LE72) and blue indicates MARV sequences (MARVUTR+tr). rLLOVcomp clones are to scale except the T7 RNA polymerase promoter (PT7), hepatitis δ ribozyme (RibHdV), T7 RNA polymerase terminator sequences (TT7), and IRins, which are enlarged for clarity. (f) Growth curve of EBOV, RESTV, and the indicated versions of rLLOVcomp in Vero E6 cells. (g) Proteomic analysis of LLOV proteins expressed in SuBK12-08 cells infected with rLLOV-ZsG-IRins-EBOVUTR+tr at a multiplicity of infection (MOI) of 1 at two days post-infection (dpi). Signal intensities of viral proteins are plotted relative to L signal intensity within the same sample. (h) RNA FISH analysis of Vero E6 cells infected with rLLOV-IRins-MARVUTR+tr at an MOI of 1 at 1 dpi. Red, negative sense (genomic) LLOV RNA clustered in viral inclusions. Cell nuclei were stained with DAPI (blue).

Based on the minigenome data, we successfully generated full-length LLOV clones that contained the EBOVUTR+tr, MARVUTR+tr, or LE72 as 5' genome ends. LE72 genome ends were chosen because this minigenome performed best in the minigenome assay (Fig. 1b) . Since there are no commercially available antibodies against LLOV, we also constructed these rLLOVcomp full-length clones with the addition of a ZsGreen reporter attached to the VP40 gene via a P2A sequence as previously described for EBOV 10 . Viral rescue was attempted by transfecting cocultures of African green monkey kidney (Vero E6) and human hepatocarcinoma (Huh7) cells with full-length clone rLLOVcomp plasmids along with codon-optimized LLOV support plasmids as previously described for the LLOV minigenome system (Fig. 1e, Supplementary Fig. 1 ) 9 . However, repeated attempts to rescue these clones were unsuccessful ( Supplementary Fig. 1 ). One striking observation regarding the published LLOV genomic sequence is the lack of gene end (GE) and gene start (GS) signals within the VP24-L intergenic region (IR), which has led to speculation that these genes may be expressed bicistronically 2 . However, this would be unique, as there are, to our knowledge, no instances of bicistronic or polycistronic genes for any nonsegmented negative sense RNA viruses outside of the bornavirus family 11, 12 . To test whether this lack of GE and GS signals might play a role in the expression of both the LLOV VP24 and L genes, we constructed and tested a bicistronic minigenome that included the wild-type VP24-L IR between firefly and renilla luciferase reporter genes (Fig. 1c) . Although we saw expression of the first reporter gene in a minigenome assay, expression of the second gene was not observed (Fig. 1d ). The addition of conserved LLOV GE and GS signals within this IR in the bicistronic minigenome (IRins), however, facilitated efficient expression of both reporter genes, indicating that there is a strict requirement for flanking GS and GE signals for each LLOV gene (Fig. 1d) .

Incorporation of the VP24-L IRins sequence into rLLOVcomp full-length genomes facilitated the rescue of three different versions of rLLOVcomp containing the ZsGreen-P2A-VP40 reporter, EBOVUTR+tr, MARVUTR+tr, and LE72 ( Fig. 1e and Supplementary Fig. 1 ) The ability of these viruses to be rescued only with the addition of the IRins sequence further highlights the strict functional need for GS and GE sequences within the LLOV genome. This raises questions about whether the published LLOV VP24-L IR sequence is potentially incomplete, possibly due to masking of IR sequences on the viral genome by abundant viral mRNA or due to possible sequencing difficulty caused by RNA secondary structures. However, since the sequencing files from the original discovery of LLOV are not publicly available, these hypotheses cannot be assessed 2 .

We next sought to compare replication kinetics of rescued Lloviu viruses with recombinant EBOV (Mayinga) and RESTV (Pennsylvania) containing ZsGreen-P2A-VP40 reporters. All three rLloviu viruses grew to lower titers in Vero E6 cells, a cell line frequently used for filovirus replication kinetics, and replicated more slowly than both the rEBOV and rRESTV, with rLLOV-LE72 representing the slowest-growing virus (Fig. 1f) . Each of the LLOV proteins was detected at abundant levels as determined by proteomic analysis of a bat (M. schreibersii) kidney cell line (SuBK12-08) 13 infected with rLLOVcomp, with a trend of viral proteins encoded closer to the 3ʹ genomic terminus producing higher relative signal intensities, indicative of greater abundance ( Fig. 1g, Supplementary Fig. 2 ). This mirrors the transcriptional gradients observed in EBOV and MARV infections 14 To gain insight into LLOV host cell tropism, we compared the ability of rLLOVcomp and rEBOV to infect two key target cell types during filovirus infections in humans, macrophages and hepatocytes 17 . Infection of both monocyte-derived macrophages (MDMs) and induced pluripotent stem cell (iPSC)-derived, primary-like hepatocytes (iHeps) 18 with rLLOV and rEBOV revealed similar infection rates, with higher infection rates with rEBOV in the iHeps at later time points ( Fig. 3a and b) . These data indicate that there is no species or cell-type tropism block that would prevent LLOV from being able to productively infect human cells. Since some of the Schreiber's bats identified during LLOV-associated die-offs showed lung infiltrates 2,5 , we also tested the ability of these viruses to infect iPSC-derived human alveolar type 2 cells (iAT2s) 19, 20 , an important lung cell type which had never been previously analyzed in the context of filovirus infections. Both rEBOV and rLLOVcomp were able to infect these cells efficiently, with rapid virus spread (Fig. 3c) . Although filovirus infections in humans have not been associated with aerosol spread, the lung is a target organ of EBOV infection in humans as shown by pulmonary histopathology of fatal EBOV disease cases 17 . In addition, EBOV infection through the aerosol route has been demonstrated in nonhuman primates 21 . EBOV and RESTV infections of pigs were associated with lung pathology and oronasal shedding of viral particles 22, 23 , indicating that there might be host and virus species specific differences in filoviral pathogenesis and transmission routes.

One highly useful application for recombinant viruses such as rLLOVcomp that are rescued with the aid of complementation with small non-coding terminal sequences from closely related viruses is the ability to study the effects of antiviral compounds on a highly authentic replicationcompetent virus. Comparing rLLOVcomp and rEBOV in both human and bat cells, we found similar inhibition of each virus in both cell types by remdesivir (Fig. 3d) , a nucleoside analog known to inhibit EBOV RNA synthesis 24 , confirming recently published results using a LLOV minigenome system 25 . Parallel analysis using U18666A, an inhibitor of the filovirus receptor Niemann-Pick C1 (NPC1) previously shown to inhibit EBOV entry 26, 27 , also showed inhibition of both viruses in both cell types (Fig. 3e) , which is in line with previous results indicating that LLOV uses NPC1 to mediate cell entry 28 . rLLOVcomp was slightly more sensitive to universal type I IFN pretreatment than rEBOV, particularly in human cells (Fig. 3f) . Conversely, while mAb114 (brand name Ebanga), a neutralizing monocolonal antibody targeting EBOV GP and approved for treatment of EBOV disease 29 , effectively blocked rEBOV infection in a dose-dependent manner at concentrations similar to those previously published 29 , it had no effect on rLLOVcomp replication ( Fig. 3g) . This corroborates previous studies showing that pan-ebolavirus anti-GP antibodies did not block entry of vesicular stomatitis virus pseudotyped with LLOV GP 30 , emphasizing the requirement of designing antivirals tailored to the virus of interest. In summary, rLLOVcomp can be used to test all steps of the viral replication cycle, including entry, viral RNA synthesis, assembly, and egress, as potential targets for antiviral therapeutics using a single system.

A hallmark of severe EBOV infection is an exacerbated inflammatory response characterized by the induction of interferon-stimulated genes and proinflammatory modulators 8 . This inflammatory response is likely driven by activated monocytes and macrophages 31 Transcriptional analysis of select genes confirmed previously observed responses to EBOV and RESTV infection 32 . While we observed robust upregulation of CXCL10 and IFNβ and, to a lesser extent, upregulation of IL6 and IL8 in EBOV-infected cells, there was only modest or no upregulation of the target genes in RESTV-and rLLOVcomp-infected cells, suggesting that similar to RESTV, rLLOVcomp does not activate human MDMs (Fig. 4c) .

Unstudied zoonotic viruses, particularly those closely related to known human pathogens, pose a threat of spillover with the potential to cause epidemics and pandemics within the human population. While many such RNA viruses, including filoviruses, have recently been discovered by unbiased sequencing technologies such as RNA-Seq 2-4 , the coverage of their genomes is typically incomplete due to missing genomic terminal sequences. Here we provide a blueprint for studying uncultured, potentially pathogenic viruses that currently only exist as incomplete sequences using LLOV, a filovirus, as an example. We used noncoding terminal sequences from other filoviruses to complement the missing LLOV sequence and we also discovered that an intergenic region lacking conserved gene start and gene end signals was nonfunctional. We leveraged the data from these complementation assays to rescue recombinant LLOV. Using rLLOVcomp, we show that there are no restrictions for LLOV infection of human cells, including primary targets of pathogenic filovirus infections such as macrophages and hepatocytes 17, 33 , seemingly indicating that spillover of LLOV to humans may be possible. While the molecular mechanisms of filovirus pathogenicity still remain elusive, previous studies have hypothesized that slower replication kinetics and muted inflammatory responses with RESTV play a role in the virus being likely nonpathogenic to humans 32, 34, 35 . Similarly, LLOV replicates slowly and does not activate MDMs, potentially pointing to LLOV not being pathogenic in humans. Therefore, based on our data with rLLOVcomp, it appears that LLOV may have a RESTV-like phenotype, having the capacity to infect humans but lacking the ability to cause disease 36 .

Particularly when trying to answer questions regarding potential pathogenicity, recombinant viruses overcome limitations of other tools that analyze only isolated steps of viral replication, such as viral genome replication and transcription (minigenome assays) or viral entry (virus-like particles) 37 . Recombinant viruses allow for a plethora of studies to address questions of potential spillover and pathogenicity, including tropism studies, analyzing host responses of primary target cells, and ultimately animal infection studies. Additionally, recombinant viruses are perfectly suited to high throughput drug screens, since they are cheaper, more scalable, and subject to fewer confounding factors such as transfection efficiency that are associated with model systems. The addition of reporter genes and use of RNA-based detection assays are also particularly beneficial for this and other purposes since reagents such as antibodies to detect these novel viruses may not be available.

One limitation to using recombinant viruses with complemented genomic termini is that these exogenous sequences could be suboptimal, making these viruses replicate more slowly and to lower titers. It was therefore surprising that we did not observe substantial sequence changes within the trailer region in the rLLOVcomp stocks, suggesting some flexibility of the viral polymerase complex in recognizing promoter elements. 

Monocyte-derived macrophages (MDMs) were generated as described previously 32 with GCDR at a 1:4 ratio onto Matrigel-coated wells and cultured in base complete serum-free differentiation medium (cSFDM) supplemented with growth factors as previously described 18, 39, 40 . Cells were then cultured for at least an additional 17 days using stage specific growth factors to specify the hepatic lineage and induce maturation.

The human iPSC line, SPC2-ST-B2, engineered to carry a tdTomato reporter targeted to the endogenous SFTPC locus 19 , underwent directed differentiation to generate iPSC-derived alveolar epithelial type 2 cells (iAT2s) in 3D Matrigel cultures using methods we have previously published 41, 42 . Briefly, to establish pure cultures of iAT2s, cells were sorted by flow cytometry to isolate SFTPC tdTomato+ cells on day 41 of differentiation, and subsequently maintained through serial passaging as self-renewing monolayered epithelial spheres by plating in Matrigel (Corning) droplets at a density of 400 cells/µl. The cultures were fed every other day with a defined serumfree distal lung maintenance media composed of base cSFDM supplemented with 3 µM CHIR99021, 10 ng/mL KGF, 50 nM dexamethasone, 0.1 mM cAMP, and 0.1 mM IBMX, referred to as "CK+DCI" media and as described previously 42 . iAT2 culture quality and purity were monitored at each passage by flow cytometry, where > 80% of cells expressing SFTPC tdTomato was observed over time, as shown previously 19, 42 . Air-liquid interface (ALI) cultures were generated as previously described 20 , with purified iAT2s seeded at 520,000 cells/cm 2 in 6.5 mm Transwell inserts (Corning) coated with hESC-Qualified Matrigel (Corning) in CK+DCI with 10 µM Rhoassociated kinase inhibitor (Sigma Y-27632). At 48h after plating, apical medium is aspirated to initiate air-liquid interface culture, and cultures were fed with CK+DCI basolateral medium every other day prior to experiments.

The following NCBI reference filovirus sequences were used for cloning where indicated and for Plasmids LLOV support plasmids (pCAGGS-NPLLOV, -VP35LLOV, -VP30LLOV, and -LLLOV) and 3L5E-Luc minigenome plasmid were described previously 9 . EBOV support plasmids (pCAGGS-NPEBOV, -VP35EBOV, -VP30EBOV, and -LEBOV) and RESTV support plasmids (pCAGGS-NPRESTV, -VP35RESTV, -VP30RESTV, and -LRESTV) were described previously 9, 43 . EBOV support plasmids have been made available through addgene (https://www.addgene.org/Elke_Muhlberger/). A plasmid expressing a codon-optimized version of T7 RNA polymerase was synthesized (GeneArt) and the pMIR β-gal plasmid was a kind gift from Matthew Jones, Boston University.

LLOV minigenomes containing hybrid LLOV L 3' untranslated region (UTR) and trailer appended with sequences from the EBOV trailer were created as follows. DNA fragments containing the LLOV L 3' UTR and trailer (nucleotides 18821-18927) appended with the full EBOV L 3' UTR and trailer (nucleotides 18220-18959) was synthesized (Twist Biosciences) and inserted into the minigenome plasmid 3L5E-Luc 9 via NotI and XmaI digestion and ligation (3L5LEfull-Luc).

Truncated versions of this minigenome were generated using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs) using the 3L5LEfull-Luc as a template.

A LLOV bicistronic minigenome was generated by cloning a synthesized fragment (Twist 

All cloning work with full-length filovirus genomes was performed in the full-length cloning laboratory of the NEIDL. The LLOV full-length clones were generated by inserting the viral genome sequence in plasmid p15AK in positive sense orientation under the control of the T7 RNA polymerase promoter (Supplementary Fig. 1 ). In this plasmid, the leader region is located immediately downstream of the T7 RNA polymerase promoter and the trailer region is flanked by a hepatitis delta (HdV) ribozyme to generate precise viral genome ends. DNA fragments comprising three portions of the full LLOV genome (NC_016144.1) were synthesized as follows. with an insert of the ZsGreen-P2A upstream of the VP40 ORF as described previously 10 were synthesized (Twist Biosciences). These fragments were cloned into the p15AK-EBOV 44 and p15AK-RESTV full-length constructs (kind gift of Thomas Hoenen, Friedrich Loeffler Institute) 35 via SphI or NcoI and SpeI, respectively.

LLOV minigenome transfections were performed as described previously 9 . Briefly, 2x10 5 293T or BHK21 cells were seeded in a 12-well plate one day prior to transfection. The next day, cells were transfected with LLOV minigenome plasmid DNA along with LLOV support plasmids encoding NP, VP35, VP30, and L as well as a plasmid expressing codon-optimized T7 RNA polymerase. As negative controls for LLOV minigenome transfections, pCDNA3.1-mCherry plasmid was used instead of L plasmid. When luciferase-expressing minigenomes were used, plasmid pMIR β-gal expressing β-galactose was co-expressed to normalize against transfection efficiency. Transfection of 293T cells was performed using TransIT ® -LT1 per manufacturer's recommendations (Mirus Bio LLC).

Recombinant LLOV rescue transfections were performed similar to rescue transfections for other filoviruses 45 Viruses EBOV Mayinga and RESTV Pennsylvania virus isolates were kindly provided by the NIH NIAID Rocky Mountain laboratories. EBOV, RESTV, and LLOV stocks were grown in Vero E6 cells and purified using ultracentrifugation through a 20% sucrose cushion as previously described (1).

Virus titers were determined in Vero E6 cells by 50% tissue culture infectious dose (TCID50) assay and calculated using the Spearman-Kärber algorithm. All work with EBOV, RESTV, and LLOV was performed under BSL-4 conditions at the NEIDL, following approved SOPs.

Monocistronic minigenome firefly luciferase assays 

For proteomic analysis, SuBK12-08 cells seeded in 6-well plates (1. SNV annotation was performed with Biostrings v2.56.0 55 and a custom R script.

Viral genomic end sequencing was performed using ViBE-Seq (sequencing of Viral Bonafide Ends), which is a novel method based on the adaptor ligation and cDNA recircularization approaches described previously [56] [57] [58] assisted with experimental planning, data analysis and interpretation. AJH and EM conceived the study. The manuscript was written by AJH and EM with assistance from the coauthors.

Bat-borne virus diversity, spillover and emergence

Discovery of an ebolavirus-like filovirus in europe

The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses

Characterization of a filovirus (Mengla virus) from Rousettus bats in China

Re-emergence of Lloviu virus in Miniopterus schreibersii bats

First Evidence of Antibodies Against Lloviu Virus in Schreiber's Bent-Winged Insectivorous Bats Demonstrate a Wide Circulation of the Virus in Spain

Taxonomy of the order Mononegavirales: update 2019

Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus

A Chimeric Lloviu Virus Minigenome System Reveals that the Bat-Derived Filovirus Replicates More Similarly to Ebolaviruses than Marburgviruses

Development of a reverse genetics system to generate a recombinant Ebola virus Makona expressing a green fluorescent protein

Transcription and replication of nonsegmented negative-strand RNA viruses

The remarkable coding strategy of borna disease virus: a new member of the nonsegmented negative strand RNA viruses

Receptor-Mediated Host Cell Preference of a Bat-Derived Filovirus

Deep sequencing identifies noncanonical editing of Ebola and Marburg virus RNAs in infected cells

Inside the Cell: Assembly of Filoviruses

Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus

Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses

A Highly Phenotyped Open Access Repository of Alpha-1 Antitrypsin Deficiency Pluripotent Stem Cells

Reconstructed Single-Cell Fate Trajectories Define Lineage Plasticity Windows during Differentiation of Human PSC-Derived Distal Lung Progenitors

SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response

Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology

Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs

Reston virus causes severe respiratory disease in young domestic pigs

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Remdesivir inhibits the polymerases of the novel filoviruses Lloviu and Bombali virus

Ebola virus entry requires the cholesterol transporter Niemann-Pick C1

Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection

Cell entry by a novel European filovirus requires host endosomal cysteine proteases and Niemann-Pick C1

Structural and molecular basis for Ebola virus neutralization by protective human antibodies

Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses

Single-Cell Profiling of Ebola Virus Disease In Vivo Reveals Viral and Host Dynamics

Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages

Pathologic features of filovirus infections in humans

Differences in Viral RNA Synthesis but Not Budding or Entry Contribute to the In Vitro Attenuation of Reston Virus Compared to Ebola Virus

The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo

Reston ebolavirus in humans and animals in the Philippines: a review

Characterization of the envelope glycoprotein of a novel filovirus, lloviu virus

Regeneration of Thyroid Function by Transplantation of Differentiated Pluripotent Stem Cells

Protocol for Directed Differentiation of Human Induced Pluripotent Stem Cells (iPSCs) to a Hepatic Lineage

Emergence of a stage-dependent human liver disease signature with directed differentiation of alpha-1 antitrypsin-deficient iPS cells

Differentiation of Human Pluripotent Stem Cells into Functional Lung Alveolar Epithelial Cells

Derivation of self-renewing lung alveolar epithelial type II cells from human pluripotent stem cells

Ebola virus VP35 antagonizes PKR activity through its Cterminal interferon inhibitory domain

An Improved Reverse Genetics System to Overcome Cell-Type-Dependent Ebola Virus Genome Plasticity

Analysis of the highly diverse gene borders in Ebola virus reveals a distinct mechanism of transcriptional regulation

Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

Ansuvimab: First Approval

QuPath: Open source software for digital pathology image analysis

A Quality Control Tool for High Throughput Sequencing Data

Fast gapped-read alignment with Bowtie 2

Improved metagenomic analysis with Kraken 2

The Sequence Alignment/Map format and SAMtools

LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cellpopulation heterogeneity from high-throughput sequencing datasets

Efficient manipulation of biological strings

iCLIP: protein-RNA interactions at nucleotide resolution

Transcriptome-wide measurement of translation by ribosome profiling

Ago2-Dependent Processing Allows miR-451 to Evade the Global MicroRNA Turnover Elicited during Erythropoiesis

Ebola and Marburg viruses: I. Some ultrastructural differences between strains when grown in Vero cells

Authors declare that they have no competing interests.

Correspondence and material requests should be addressed to EM.